|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.040 USD | +4.00% |
|
-14.75% | -68.96% |
Summary: VYNE Therapeutics Inc.
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: VYNE Therapeutics Inc.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: VYNE Therapeutics Inc.
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings Chart: VYNE Therapeutics Inc.
Source: Surperformance
| Fundamentals | Valuation | Revisions of Fundamental Estimates | Capi.($) | ||
|---|---|---|---|---|---|
| - | - | 17.33M | |||
| 62.17B | |||||
| 35.61B | |||||
| 28.58B | |||||
| 24.74B | |||||
| 12.75B | |||||
| 12.38B | |||||
| Average | 25.18B | ||||
| Weighted average by Cap. |
Investor
-
Trader
ESG MSCI
-
Financials
Sales growth
EPS Growth
Profitability
-
Net margin
-
Financial Health
-
Valuation
P/E ratio
-
EV/REVENUE
-
EV/EBITDA
-
PBR
-
Yield
-
Revisions
1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision
Business Predictability
Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VYNE Stock
- Ratings VYNE Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
